Additional Information
Book Details
Abstract
Endocrine Surgery meets the needs of surgeons in higher training and practising consultants for a contemporary and evidence-based account of this sub-specialty that is relevant to their general surgical practice. It is a practical reference source incorporating the most current information on recent developments, management issues and operative procedures. The text is thoroughly referenced and supported by evidence-based recommendations wherever possible, distinguishing between strong evidence to support a conclusion, and evidence suggesting that a recommendation can be reached on the balance of probabilities.
This is a title in the Companion to Specialist Surgical Practice series whose eight volumes are an established and highly regarded source of information for the specialist general surgeon.
- The Companion to Specialist Surgical Practice series provides a current and concise summary of the key topics within each major surgical sub-specialty.
- Each volume highlights evidence-based practice both in the text and within the extensive list of references at the end of every chapter.
- An expanded authorship team across the series includes additional European and World experts with an increased emphasis on global practice.
- The contents of the series have been extensively revised in line with recently published evidence.
- All the chapters reflect the multidisciplinary approach to the subject with up-to-date information on cytopathology, assays of hormones, localisation techniques, anaesthetic requirements, genetic implications and, of course, histopathology and adjuvant treatments.
- Minimally invasive approaches continue to be promoted and developed throughout the book.
- The text has a closer emphasis on practical and pragmatic approaches to clinical scenarios.
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Cover | ||
Endocrine Surgery: A COMPANION TO SPECIALIST SURGICAL PRACTICE | iii | ||
Copyright | iv | ||
Contents | v | ||
Contributors | vii | ||
Series Editors' preface | ix | ||
Editor's preface | xi | ||
Evidence-based practice in surgery | xiii | ||
Chapter 1: Parathyroid disease | 1 | ||
Part 1. Parathyroid disease, syndromes and pathophysiology | 1 | ||
Introduction | 1 | ||
Embryology and anatomy | 1 | ||
Calcium and parathyroid hormone (PTH) regulation | 2 | ||
Primary hyperparathyroidism | 3 | ||
Incidence | 3 | ||
Clinical manifestations | 3 | ||
Diagnosis | 3 | ||
Normocalcaemic hyperparathyroidism | 4 | ||
Hypercalcaemic crisis | 5 | ||
Surgical indications | 8 | ||
Imaging and localisation | 9 | ||
Ultrasound (US) | 9 | ||
Computed tomography (CT) | 11 | ||
Magnetic resonance imaging (MRI) | 11 | ||
Thallium-201–technetium-99 m pertechnetate scan (Tl–99mTc scan) | 11 | ||
Technetium-99 m sestamibi scan (sestamibi scan) | 12 | ||
Parathyroid angiography and venous sampling for PTH | 14 | ||
Pathology | 14 | ||
Adenoma | 15 | ||
Double adenoma | 15 | ||
Hyperplasia | 15 | ||
Carcinoma | 15 | ||
Secondary hyperparathyroidism (SHP) | 16 | ||
Pathogenesis | 16 | ||
Hypocalcaemia and hyperphosphataemia | 16 | ||
Decreased synthesis of calcitriol | 16 | ||
Bony resistance to PTH | 16 | ||
Changes in PTH set point | 16 | ||
Aluminium intoxication | 16 | ||
Presentation | 17 | ||
Osseous lesions | 17 | ||
Pruritus | 17 | ||
Metastatic calcification | 17 | ||
Calciphylaxis | 17 | ||
Treatment | 17 | ||
Tertiary hyperparathyroidism | 17 | ||
References | 18 | ||
Part 2. Operative strategy for themanagement of parathyroid disease | 21 | ||
Primary hyperparathyroidism | 21 | ||
Conventional open parathyroidectomy | 21 | ||
Basic principles of parathyroid surgery | 21 | ||
Management of surgical procedure | 22 | ||
The search for superior parathyroid (P IV) | 22 | ||
The search for inferior parathyroid (P III) | 23 | ||
Evaluation of the initial bilateral exploration | 23 | ||
Continuation of the exploration | 24 | ||
The parathyroidectomy | 25 | ||
Solitary parathyroid adenoma (Fig. 1.12) | 25 | ||
Sporadic multiglandular disease | 25 | ||
Familial hyperparathyroidism | 26 | ||
Primary hyperparathyroidism in MEN1 | 26 | ||
Primary hyperparathyroidism in MEN2A | 26 | ||
Parathyroid carcinoma | 27 | ||
Parathyroidectomy associated with thyroid excisions | 27 | ||
Overall results of conventional open parathyroidectomy | 27 | ||
Minimally invasive parathyroidectomy (MIP) | 28 | ||
Unilateral neck exploration | 28 | ||
Open minimally invasive parathyroidectomy (OMIP) | 28 | ||
Minimally invasive radio-guided parathyroidectomy (MIRP) | 29 | ||
Endoscopic parathyroidectomy | 29 | ||
MIP in the broader context | 30 | ||
Intraoperative parathyroid hormone assay (ioPTH) | 31 | ||
Re-operation for persistent or recurrent primary hyperparathyroidism (PHP) | 31 | ||
Analysis of causes of failure | 31 | ||
Management | 31 | ||
Confirmation of the diagnosis | 31 | ||
Case history | 31 | ||
Preoperative evaluation | 32 | ||
Methods of re-operation | 32 | ||
The posterolateral approach (‘back-door’ approach) | 33 | ||
The thyrothymic approach (‘front-door’ approach) | 33 | ||
Revision of the transverse cervicotomy | 33 | ||
Mediastinal approaches | 33 | ||
Other focused approaches | 33 | ||
Additional procedures | 33 | ||
Results | 33 | ||
Secondary hyperparathyroidism (SHP) | 34 | ||
Hyperparathyroidism secondary to compensatory stimulation of parathyroid hormone | 34 | ||
Surgical strategies | 34 | ||
Perioperative care | 35 | ||
Persistent and recurrent SHP | 35 | ||
Lithium-induced hyperparathyroidism | 36 | ||
Tertiary hyperparathyroidism | 36 | ||
References | 37 | ||
Chapter 2: The thyroid gland | 41 | ||
Background | 41 | ||
Embryology, surgical anatomy and physiology | 41 | ||
Embryology | 41 | ||
Thyroid anatomy | 41 | ||
Recurrent laryngeal nerve and external branch of superior laryngeal nerve anatomy | 41 | ||
Parathyroid anatomy | 42 | ||
Thyroid physiology | 42 | ||
Clinical history and examination | 43 | ||
Investigation of the thyroid | 43 | ||
Blood tests | 44 | ||
Thyroid function tests | 44 | ||
Thyroid antibodies | 44 | ||
Thyroglobulin antibody | 44 | ||
Thyroid peroxidase antibody | 45 | ||
TSH receptor antibody | 45 | ||
Biomarkers of malignant disease | 45 | ||
Thyroglobulin | 45 | ||
Calcitonin | 45 | ||
Carcinoembryonic antigen | 45 | ||
Imaging studies | 45 | ||
Ultrasonography | 45 | ||
Nuclear medicine studies | 45 | ||
Computed tomography | 45 | ||
Tissue diagnosis | 46 | ||
Incidental thyroid pathology | 46 | ||
Surgical pathologies of the thyroid | 47 | ||
Benign conditions | 47 | ||
Benign goitre | 47 | ||
Causes of multinodular goitre | 48 | ||
Iodine deficiency | 48 | ||
Genetics | 48 | ||
Goitrogens | 48 | ||
Gender | 48 | ||
Drugs | 48 | ||
Pathogenesis | 48 | ||
Management of benign MNG | 48 | ||
Thyroid cysts | 48 | ||
Malignant conditions | 49 | ||
Molecular biology of thyroid cancers | 49 | ||
Papillary thyroid carcinoma | 49 | ||
Follicular thyroid carcinoma | 49 | ||
Differentiated thyroid cancers (PTC and FTC) | 49 | ||
Risk factors | 49 | ||
Pathology | 50 | ||
Papillary thyroid carcinoma | 50 | ||
Follicular thyroid carcinoma | 50 | ||
Staging | 51 | ||
Work-up | 51 | ||
Management of DTC | 52 | ||
Surgery of DTC | 52 | ||
Extent of thyroidectomy | 52 | ||
Contraindications to total thyroidectomy | 53 | ||
Lymph node dissection | 53 | ||
Adjuvant treatments | 54 | ||
Follow-up | 54 | ||
Poorly differentiated thyroid cancer (PDTC) | 54 | ||
Medullary thyroid carcinoma | 54 | ||
Pathology | 54 | ||
Clinical features | 55 | ||
Diagnosis | 55 | ||
Treatment | 55 | ||
Prognosis | 56 | ||
Follow-up | 56 | ||
Anaplastic thyroid carcinoma | 56 | ||
Other malignancies | 56 | ||
Primary thyroid lymphoma | 56 | ||
Squamous cell carcinoma | 57 | ||
Metastatic carcinoma to the thyroid | 57 | ||
Hyperthyroidism | 57 | ||
Causes | 57 | ||
Clinical features | 57 | ||
Investigations | 57 | ||
Diagnosis of thyrotoxicosis | 57 | ||
Determination of aetiology | 58 | ||
End-organ effects | 59 | ||
Management | 59 | ||
Symptomatic management | 59 | ||
Management – Graves' disease | 59 | ||
131 I | 59 | ||
ATD | 59 | ||
Management – TMNG | 59 | ||
Management – TA | 59 | ||
Surgical indications | 59 | ||
Operative strategy | 59 | ||
Preoperative considerations | 59 | ||
Operative considerations | 60 | ||
Postoperative considerations | 61 | ||
Thyroiditis | 61 | ||
Subacute thyroiditis (de Quervain's thyroiditis) | 61 | ||
Autoimmune thyroiditis (Hashimoto's thyroiditis) | 61 | ||
Riedel's thyroiditis | 61 | ||
Acute suppurative thyroiditis | 61 | ||
Postpartum thyroiditis | 61 | ||
Surgery of the thyroid | 62 | ||
Unilateral total thyroid lobectomy (hemithyroidectomy) | 62 | ||
Preparation | 62 | ||
Exposure | 62 | ||
Mobilisation | 62 | ||
RLN and parathyroid glands | 63 | ||
Total thyroidectomy | 64 | ||
Retrosternal goitre | 64 | ||
Recurrent goitre | 64 | ||
Neuromonitoring | 64 | ||
Sutureless thyroidectomy | 64 | ||
Minimally invasive and robotic surgery | 64 | ||
Complications of thyroidectomy | 65 | ||
Recurrent laryngeal nerve injury | 65 | ||
External branch of superior laryngeal nerve injury | 65 | ||
Hypoparathyroidism | 65 | ||
Recurrent hyperthyroidism | 65 | ||
Thyroid crisis/storm | 65 | ||
Haemorrhage/airway obstruction | 65 | ||
Miscellaneous | 66 | ||
References | 66 | ||
Chapter 3: The adrenal glands | 70 | ||
Anatomy | 70 | ||
Blood supply and lymphatic drainage | 70 | ||
Nerve supply | 70 | ||
Microscopic anatomy | 70 | ||
Embryology | 71 | ||
Physiology | 71 | ||
Adrenal medulla | 71 | ||
Catecholamine synthesis and metabolism | 71 | ||
Catecholamine physiological effects | 72 | ||
Adrenal cortex | 72 | ||
Mineralocorticoids | 72 | ||
Glucocorticoids | 73 | ||
Sex steroids | 73 | ||
Adrenal incidentaloma | 73 | ||
Case study 1 | 73 | ||
Definition and incidence | 73 | ||
Aetiology | 73 | ||
Investigation | 74 | ||
Biochemistry | 74 | ||
Biopsy | 74 | ||
Imaging | 74 | ||
Management | 75 | ||
Case study 1 (discussion) | 75 | ||
Adrenocortical carcinoma | 76 | ||
Case study 2 | 76 | ||
Incidence and aetiology | 76 | ||
Clinical features | 76 | ||
Biochemistry | 76 | ||
Imaging | 76 | ||
Diagnosis and staging | 77 | ||
Treatment | 77 | ||
Surgery | 77 | ||
Medical | 77 | ||
Prognosis | 77 | ||
Case study 2 (discussion) | 78 | ||
Phaeochromocytoma and paraganglioma | 78 | ||
Case study 3 | 78 | ||
Incidence and aetiology | 78 | ||
Clinical presentation | 80 | ||
Biochemical diagnosis | 80 | ||
Imaging | 80 | ||
Medical management | 81 | ||
Surgical management | 82 | ||
Case study 4 | 82 | ||
Malignant phaeochromocytoma | 82 | ||
Phaeochromocytoma in pregnancy | 82 | ||
Case study 3 (discussion) | 83 | ||
Case study 4 (discussion) | 84 | ||
Cushing's syndrome | 84 | ||
Case study 5 | 84 | ||
Definition and aetiology | 84 | ||
Clinical features | 84 | ||
Biochemical diagnosis | 84 | ||
ACTH-dependent Cushing's syndrome | 86 | ||
Imaging | 86 | ||
Chapter 4: Familial endocrine disease: genetics, clinical presentation and management | 98 | ||
Introduction | 98 | ||
A brief overview of clinical endocrine genetics | 98 | ||
Multiple endocrine neoplasia type 1 (MEN1) | 100 | ||
Genetics | 100 | ||
Presentation | 101 | ||
Primary hyperparathyroidism | 101 | ||
Enteropancreatic islet tumours | 101 | ||
Pituitary tumours | 101 | ||
Foregut carcinoids | 101 | ||
Adrenocortical tumours | 102 | ||
Cutaneous manifestations | 102 | ||
Diagnosis | 102 | ||
Management | 102 | ||
Primary hyperparathyroidism | 102 | ||
Enteropancreatic islet tumours | 102 | ||
Pituitary tumours | 104 | ||
Foregut carcinoids | 104 | ||
Surveillance and screening | 104 | ||
Genetic testing | 104 | ||
Biochemical and radiological surveillance | 104 | ||
MEN1: differential diagnosis | 105 | ||
Familial isolated pituitary adenoma (FIPA) | 105 | ||
Presentation | 105 | ||
Management | 105 | ||
Familial intestinal carcinoid | 105 | ||
Multiple endocrine neoplasia type 2 | 106 | ||
Genetics | 106 | ||
Presentation | 107 | ||
Chapter 5: Endocrine tumours of the pancreas | 125 | ||
Introduction | 125 | ||
Insulinoma | 125 | ||
Presentation | 125 | ||
Diagnosis | 127 | ||
Supervised standard fasting test | 127 | ||
Nesidioblastosis | 128 | ||
Management | 129 | ||
Medical management of hypoglycaemia | 129 | ||
Preoperative tumour localisation | 129 | ||
Non-invasive imaging studies | 129 | ||
Invasive localising procedures | 129 | ||
Operative management | 131 | ||
Open exploration | 131 | ||
Resection of insulinoma | 132 | ||
Insulinoma and MEN1 | 132 | ||
Laparoscopic surgery | 133 | ||
Outcome | 133 | ||
Gastrinoma | 133 | ||
Patient presentation | 134 | ||
Diagnosis | 134 | ||
Management | 134 | ||
Medical control of gastric acid hypersecretion | 134 | ||
Preoperative tumour localisation | 136 | ||
Non-invasive tumour-localising studies | 136 | ||
Invasive tumour-localising modalities | 137 | ||
Surgery for tumour eradication | 137 | ||
Operative approach | 137 | ||
Intraoperative manoeuvres to find the primary gastrinoma | 137 | ||
Tumour resection | 138 | ||
Gastrinoma and MEN1 | 139 | ||
Outcome | 140 | ||
Non-functional pNETs | 140 | ||
Other rare endocrine tumours of the pancreas | 140 | ||
Malignant pNETs | 141 | ||
Evaluation of metastatic disease | 141 | ||
Surgical management | 141 | ||
Non-surgical management | 142 | ||
References | 143 | ||
Chapter 6: Gastrointestinal neuroendocrine tumours | 147 | ||
Introduction | 147 | ||
Oesophageal NETs | 148 | ||
Gastric NETs | 149 | ||
Type 1: gastric NETs associated with chronic atrophic gastritis | 149 | ||
Type 2: NETs associated with ZES in MEN1 patients | 150 | ||
Type 3: sporadic gastric NETs | 151 | ||
Gastrinoma | 152 | ||
Poorly differentiated gastric neuroendocrine carcinomas | 152 | ||
Clinical evaluation | 152 | ||
Symptoms and patient history | 152 | ||
Diagnosis | 152 | ||
Treatment | 153 | ||
CAG-associated type 1 gastric NETs | 153 | ||
MEN1-related type 2 gastric NETs | 153 | ||
Sporadic type 3 gastric NETs | 154 | ||
Poorly differentiated NECs | 154 | ||
Duodenal NETs | 154 | ||
Gastrinomas | 154 | ||
Somatostatin-rich NETs | 154 | ||
Gangliocytic paragangliomas | 155 | ||
Other duodenal NETs | 155 | ||
Duodenal NECs | 155 | ||
Pancreatic NETs | 155 | ||
Jejuno-ileal (small-intestinal) NETs (midgut carcinoids) | 156 | ||
Morphological features | 156 | ||
Clinical symptoms | 157 | ||
Carcinoid syndrome | 158 | ||
Diagnosis | 158 | ||
Biochemistry | 158 | ||
Pentagastrin provocation test | 159 | ||
Radiology | 159 | ||
Computed tomography | 159 | ||
Ultrasound | 159 | ||
OctreoScan® | 159 | ||
Positron emission tomography (PET) | 159 | ||
Histology | 159 | ||
Surgery | 160 | ||
Surgical technique | 161 | ||
Liver metastases | 164 | ||
Liver surgery | 164 | ||
Radiofrequency or microwave ablation | 165 | ||
Liver embolisation | 165 | ||
Liver transplantation | 166 | ||
Prophylaxis against carcinoid crisis | 166 | ||
Medical treatment | 167 | ||
Radiotherapy | 167 | ||
Survival | 167 | ||
Appendiceal NETs | 168 | ||
Atypical goblet-cell NETs | 169 | ||
Colon NETs | 169 | ||
Rectal NETs | 169 | ||
Presentation | 169 | ||
Diagnosis and immunohistochemistry | 170 | ||
Treatment | 171 | ||
Outcome | 171 | ||
Recommendations | 171 | ||
References | 173 | ||
Chapter 7: Clinical governance, ethics and medicolegal aspects of endocrine surgery | 178 | ||
Clinical governance | 178 | ||
What is good practice? | 179 | ||
Who should perform surgery on the endocrine glands? | 179 | ||
The advantages of subspecialisation | 180 | ||
Thyroid surgery | 181 | ||
Chapter 8: The salivary glands | 191 | ||
Introduction | 191 | ||
Surgical anatomy | 191 | ||
The parotid gland | 191 | ||
Facial nerve | 191 | ||
The submandibular gland | 192 | ||
The sublingual gland | 192 | ||
Investigations | 192 | ||
Clinical assessment | 192 | ||
Imaging | 192 | ||
Fine-needle aspiration cytology | 193 | ||
Sialendoscopy | 194 | ||
Non-neoplastic disease of the salivary glands | 194 | ||
Inflammatory conditions | 194 | ||
Acute viral inflammation | 194 | ||
Acute suppurative sialadenitis | 195 | ||
Chronic inflammatory conditions | 195 | ||
Mycobacterium tuberculosis | 195 | ||
Atypical tuberculosis | 195 | ||
Cat-scratch disease | 195 | ||
Actinomycosis | 196 | ||
Sarcoidosis | 196 | ||
Sjögren's syndrome | 196 | ||
Human immunodeficiency virus | 197 | ||
Sialolithiasis | 197 | ||
Treatment | 197 | ||
Interventional sialendoscopy | 198 | ||
Non-inflammatory conditions | 198 | ||
Sialadenosis/sialosis | 198 | ||
Salivary gland cysts | 198 | ||
Post-radiotherapy xerostomia | 198 | ||
Neoplastic disease | 198 | ||
Benign epithelial neoplasms | 199 | ||
Pleomorphic adenoma | 199 | ||
Warthin's tumour | 200 | ||
Other benign epithelial neoplasms | 200 | ||
Management of benign epithelial neoplasms | 200 | ||
Recurrent benign epithelial neoplasms | 201 | ||
Benign non-epithelial neoplasms | 201 | ||
Malignant epithelial neoplasms | 201 | ||
Mucoepidermoid carcinoma | 201 | ||
Adenoid cystic carcinoma | 201 | ||
Acinic cell carcinoma | 202 | ||
Polymorphous low-grade adenocarcinoma | 202 | ||
Carcinoma ex-pleomorphic adenoma | 202 | ||
Management of epithelial malignancies | 202 | ||
Malignant non-epithelial neoplasm | 202 | ||
Metastatic disease to the major salivary glands | 202 | ||
Surgical principles | 203 | ||
Parotid surgery | 203 | ||
Partial parotidectomy | 203 | ||
Deep lobe parotidectomy/total parotidectomy with facial nerve preservation | 205 | ||
Radical parotidectomy | 205 | ||
Extended radical parotidectomy | 205 | ||
Parapharyngeal space tumours | 205 | ||
Submandibular gland surgery | 205 | ||
Minor salivary gland surgery | 206 | ||
Surgical complications | 206 | ||
Intraoperative complications | 206 | ||
Facial nerve palsy | 206 | ||
Frey's syndrome | 206 | ||
Other postoperative complications | 207 | ||
References | 207 | ||
Index | 211 |